Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

LEASES (Tables)

9 Months Ended

Sep. 30, 2023

The components of our operating lease expense were as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Fixed operating lease expense	$	166	$	1,340	$	944	$	4,020
Variable operating lease expense		75		211		105		602
Total operating lease expense	$	241	$	1,551	$	1,049	$	4,622

Supplemental information related to our operating lease were as follow (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Cash payments included in the measurement of operating lease liabilities	$	178	$	2,630	$	1,352	$	7,856

Supplemental information related to our operating sublease was as follow (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Fixed sublease expense	$	—	$	1,095	$	365	$	3,285
Variable sublease expense		—		232		77		682
Sublease income		—		(1,327)		(442)		(3,967)
Net	$	—	$	—	$	—	$	—

The following table presents the future lease payments as of September 30, 2023 (in thousands):


Remainder of 2023	$	182
2024		739
2025		301
Total minimum payments required	$	1,222